NSC 42834

• Description :

  NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

• Product Name Alternative :

  JAK2 Inhibitor V; Z3

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  JAK

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/NSC-42834.html

• Purity :

  96.85

• Solubility :

  DMSO : ≥ 100 mg/mL|Ethanol : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=CC=CC=C1)C(CCC2=NC=CC=C2)(C)CCC3=NC=CC=C3

• Molecular Formula :

  C23H24N2O

• Molecular Weight :

  344.45

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Jacqueline Sayyah, Andrew Magis, David A. Ostrov, et al. Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth . Mol Cancer Ther 2008;7 (8) :2308-18.|[2]Jacqueline Sayyah, Peter P. Sayeski. Jak2 inhibitors: Rationale and role as therapeutic agents in hematologic malignancies. Current Oncology Reports. 2009, 11 (2) : 117-124.|[3]Ehab Atallah , Srdan Verstovsek . Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Review of Anticancer Therapy. 2009,9 (5) :663-670.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  JAK2

• CAS Number :

  [195371-52-9]